Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[unchecked revision][checked revision]
← Older edit
VisualWikitext
No edit summary
Tags: Visual edit Mobile edit Mobile web edit
No edit summary
 
(147 intermediate revisions by 8 users not shown)
Line 1: Line 1:
{| class="wikitable" style="margin:auto"
Welcome!
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
 
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.'''
 
*For assignments, please see the "Author" column below (highlighted blue).
 
*If empty (no name is present), please volunteer to create content for that disease!
*If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
 
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.
 
__TOC__
 
<br />
{| class="wikitable sortable" style="margin:auto"
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big>
|-
|-
!Disease (5th Edition)!!Page Type!!Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)!!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
!Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Correlated Prior Author (4th Edition)
!Content Status (4th Edition)(Pending or Complete)
!Prior Content Status (4th Edition)(Pending or Complete)
!Date of Last Editor Review (4th Edition)
!Prior Date of Last Editor Review (4th Edition)
!Notes (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)
|
====CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)====
|
|
----<br />
----<br />
Line 15: Line 32:
----<br />
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra
|4/8/24
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 34: Line 65:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease|| || || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 41: Line 72:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Chronic myeloid leukaemia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||PENDING|| || || || ||FQR|| ||
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
Line 48: Line 79:
|
|
|-
|-
|Chronic neutrophilic leukaemia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING
| || || || ||FQR|| ||
|Chronic Neutrophilic Leukemia (CNL)
|Chronic Neutrophilic Leukemia (CNL)
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
Line 55: Line 87:
|
|
|-
|-
|Chronic eosinophilic leukaemia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||PENDING
| || || || ||FQR|| ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chelsea D. Kramish; Daynna J.Wolff
|Chelsea D. Kramish; Daynna J.Wolff
Line 62: Line 95:
|
|
|-
|-
|Polycythaemia vera||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||PENDING
| || || || ||FQR|| ||
|Polycythemia Vera (PV)
|Polycythemia Vera (PV)
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
Line 69: Line 103:
|
|
|-
|-
|Essential thrombocythaemia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||PENDING
| || || || ||FQR|| ||
|Essential Thrombocythemia (ET)
|Essential Thrombocythemia (ET)
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
Line 76: Line 111:
|
|
|-
|-
|Primary myelofibrosis||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING
| || || || ||FQR|| ||
|Primary Myelofibrosis (PMF)
|Primary Myelofibrosis (PMF)
|T. Niroshi Senaratne, UCLA
|T. Niroshi Senaratne, UCLA
Line 83: Line 119:
|
|
|-
|-
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' | || || || || ||FQR|| ||
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING
| || || || ||FQR|| ||
|Juvenile Myelomonocytic Leukemia (JMML)
|Juvenile Myelomonocytic Leukemia (JMML)
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
Line 94: Line 131:
|FQR has emailed SR several times, last 4/20/22
|FQR has emailed SR several times, last 4/20/22
|-
|-
|Myeloproliferative neoplasm, NOS||Disease|| || || || || ||FQR|| ||
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING
| || || || ||FQR|| ||
|Myeloproliferative Neoplasm (MPN), Unclassifiable
|Myeloproliferative Neoplasm (MPN), Unclassifiable
|Thomas Lee, MD, PhD, University of California, Los Angeles
|Thomas Lee, MD, PhD, University of California, Los Angeles
Line 101: Line 155:
|
|
|-
|-
|Cutaneous mastocytosis||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING
| || || || ||FQR|| ||
|Cutaneous Mastocytosis
|Cutaneous Mastocytosis
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
Line 108: Line 163:
|
|
|-
|-
|Systemic mastocytosis||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| ||
|Systemic Mastocytosis
|Systemic Mastocytosis
|'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University
|Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University  Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University
|Complete
|Complete
|
|
|
|
|-
|-
|Mast cell sarcoma||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING
| || || || ||FQR|| ||
|Mast Cell Sarcoma
|Mast Cell Sarcoma
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
Line 122: Line 178:
|
|
|-
|-
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
Line 129: Line 186:
|
|
|-
|-
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease||PENDING
| || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 136: Line 194:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease||Eric McGinnis (assigned to new 5th edition page - FQR please follow-up to confirm)|| || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with biallelic TP53 inactivation|Myelodysplastic neoplasm with biallelic TP53 inactivation]]||Disease||Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?)|| || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 143: Line 201:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts|Myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 150: Line 208:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm, hypoplastic|Myelodysplastic neoplasm, hypoplastic]]||Disease|| || || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 157: Line 215:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm with increased blasts||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic Syndrome (MDS) with Excess Blasts
|Myelodysplastic Syndrome (MDS) with Excess Blasts
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 164: Line 223:
|
|
|-
|-
|Childhood myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Refractory Cytopenia of Childhood
|Refractory Cytopenia of Childhood
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 171: Line 247:
|
|
|-
|-
|Childhood myelodysplastic neoplasm with increased blasts||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Refractory Cytopenia of Childhood
|Refractory Cytopenia of Childhood
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 178: Line 255:
|
|
|-
|-
|Chronic myelomonocytic leukaemia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING
| || || || ||FQR|| ||
|Chronic Myelomonocytic Leukemia (CMML)
|Chronic Myelomonocytic Leukemia (CMML)
|Linsheng Zhang, MD, PhD
|Linsheng Zhang, MD, PhD
Line 185: Line 263:
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING
| || || || ||FQR|| ||
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
|Linsheng Zhang, MD, PhD
|Linsheng Zhang, MD, PhD
Line 192: Line 271:
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
Line 199: Line 279:
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
Line 206: Line 287:
|
|
|-
|-
|Acute promyelocytic leukaemia with PML::RARA fusion
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
|Disease
|Disease
|(Rabail Aslam, MD)
Shashi Shetty, Ph.D.
|7/1/24
|
|
|
|Pending
|
|
|
|
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
Line 222: Line 304:
|
|
|-
|-
|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
|Disease
|Disease
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|9/22/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 238: Line 320:
|
|
|-
|-
|Acute myeloid leukaemia with CBFB::MYH11 fusion
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
|Disease
|Disease
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|9/22/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 254: Line 336:
|
|
|-
|-
|Acute myeloid leukaemia with DEK::NUP214 fusion
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
|Disease
|Disease
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|
|JH_MS
|JH_MS
Line 270: Line 352:
|
|
|-
|-
|Acute myeloid leukaemia with RBM15::MRTFA fusion
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
|Disease
|Disease
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Complete
|
|
|
|JH_MS
|JH_MS
Line 286: Line 384:
|
|
|-
|-
|Acute myeloid leukaemia with BCR::ABL1 fusion
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
|Disease
|Disease
|
|(Xinxiu Xu)(trainee) Malini Sathanoori, Ph.D.
|
|4/15/25
|
|
|
|
Line 302: Line 400:
|
|
|-
|-
|Acute myeloid leukaemia with KMT2A rearrangement
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
|Disease
|Disease
|(Rabail Aslam, MD)
Shashi Shetty, Ph.D.
|7/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 318: Line 417:
|
|
|-
|-
|Acute myeloid leukaemia with MECOM rearrangement
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
|Disease
|Disease
|Gordana Raca MD PhD,
|9/8/25
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 334: Line 433:
|Need permission for figure? Update WHO?
|Need permission for figure? Update WHO?
|-
|-
|Acute myeloid leukaemia with NUP98 rearrangement
|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]]
|Disease
|Disease
|Eric McGinnis, MD, Fatma Al-Bulushi (trannee)
|12/20/23
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 350: Line 449:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Acute myeloid leukaemia with NPM1 mutation
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]]
|Disease
|Disease
|
|
Line 359: Line 458:
|JH_MS
|JH_MS
|
|
|
|emailed request on 7/16/24. No response as of 9/7/25.
Prior author: Xinjie Xu, PhD, FACMG
 
Open to new author
|Acute Myeloid Leukemia (AML) with Mutated NPM1
|Acute Myeloid Leukemia (AML) with Mutated NPM1
|Xinjie Xu, PhD, FACMG
|Xinjie Xu, PhD, FACMG
|Complete
|Complete
|
|
|Add WHO reference
|Add WHO reference<br />
|-
|-
|Acute myeloid leukaemia with CEBPA mutation
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
|Disease
|Disease
|
|(Xinxiu Xu)(trainee) Malini Sathanoori, Ph.D.
|
|4/15/25
|
|
|
|
Line 382: Line 484:
|
|
|-
|-
|Acute myeloid leukaemia, myelodysplasia-related
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]]
|Disease
|Disease
|
|
Line 391: Line 493:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University
Line 398: Line 500:
|
|
|-
|-
|Acute myeloid leukaemia with other defined genetic alterations
|[[HAEM5:Acute myeloid leukaemia with other defined genetic alterations|Acute myeloid leukaemia with other defined genetic alterations]]
|Disease
|Disease
|
|
Line 414: Line 516:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Acute myeloid leukaemia with minimal differentiation
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]]
|Disease
|Disease
|
|
Line 423: Line 525:
|JH_MS
|JH_MS
|
|
|
|Prior author: Celeste Eno, PhD
 
Open to new author
|Acute Myeloid Leukemia (AML) with Minimal Differentiation
|Acute Myeloid Leukemia (AML) with Minimal Differentiation
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
Line 430: Line 534:
|
|
|-
|-
|Acute myeloid leukaemia without maturation
!Disease (5th Edition)
|Disease
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
|Disease
|Jennelle C. Hodge, PhD
|
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 446: Line 566:
|
|
|-
|-
|Acute myeloid leukaemia with maturation
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
|Disease
|Disease
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|
|JH_MS
|JH_MS
Line 462: Line 582:
|
|
|-
|-
|Acute basophilic leukaemia
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
|Disease
|Disease
|Ashwini Yenamandra PhD FACMG
|5/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 478: Line 598:
|
|
|-
|-
|Acute myelomonocytic leukaemia
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]]
|Disease
|Disease
|
|
Line 487: Line 607:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Myelomonocytic Leukemia
|Acute Myelomonocytic Leukemia
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
Line 494: Line 614:
|
|
|-
|-
|Acute monocytic leukaemia
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]]
|Disease
|Disease
|
|
Line 503: Line 623:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Monoblastic and Monocytic Leukemia
|Acute Monoblastic and Monocytic Leukemia
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
Line 510: Line 630:
|
|
|-
|-
|Acute erythroid leukaemia
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
|Disease
|Disease
|Ashwini Yenamandra PhD FACMG
|5/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 526: Line 646:
|
|
|-
|-
|Acute megakaryoblastic leukaemia
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]]
|Disease
|Disease
|
|
Line 535: Line 655:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Megakaryoblastic Leukemia (AMKL)
|Acute Megakaryoblastic Leukemia (AMKL)
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
Line 542: Line 662:
|
|
|-
|-
|Myeloid sarcoma
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
|Disease
|Disease
|Yalda Naeini
|6/11/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 559: Line 679:
|-
|-
|RESOLVE 4th edition AML-Related NON-WHO entities content
|RESOLVE 4th edition AML-Related NON-WHO entities content
|Acute Myeloid Leukemia (AML) with Mutated FLT3 + Acute Myeloid Leukemia (AML) with NUP214-ABL1 + Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6
|[[HAEM4:Acute Myeloid Leukemia (AML) with Mutated FLT3|Acute Myeloid Leukemia (AML) with Mutated FLT3]] + [[HAEM4:Acute Myeloid Leukemia (AML) with NUP214-ABL1|Acute Myeloid Leukemia (AML) with NUP214-ABL1]] + [[HAEM4:Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6|Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6]]
|ISSUE - FIX
|ISSUE- FIX
 
 
Resolve Non-WHO entities
|
|
|
|
Line 574: Line 697:
|
|
|-
|-
|Myeloid neoplasm post cytotoxic therapy
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
|Disease
|Disease
|(Rabail Aslam, MD)
Shashi Shetty, Ph.D.
|7/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 586: Line 710:
|Therapy-Related Myeloid Neoplasms
|Therapy-Related Myeloid Neoplasms
|Shawn A. Silver, DO, Shashi Shetty, Ph.D.
|Shawn A. Silver, DO, Shashi Shetty, Ph.D.
|
|Complete
|
|
|Check reference format
|Check reference format
|-
|-
|Myeloid neoplasms associated with germline predisposition
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
|Disease
|Disease
|ISSUE - FIX
|Malini Sathanoori, Ph.D.
|
|12/6/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|
|
|Multiple pages including overview page ([[Myeloid Neoplasms with Germline Predisposition|Myeloid Neoplasms with Germline Predisposition - Compendium of Cancer Genome Aberrations (ccga.io)]]) and 6 disease pages ( [[HAEM4:Acute Myeloid Leukaemia with Germline CEBPA Mutation]], [[HAEM4:Myeloid Neoplasms with Germline DDX41 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ETV6 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline GATA2 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline RUNX1 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ANKRD26 Mutation]])
|
|See links from instructions on the 5th edition page
|
|Complete
|
|Most were re-reviewed by MS on 03/02/2021
|
|For page Acute Myeloid Leukaemia with Germline CEBPA Mutation - Note by MS of "Review completed, awaiting some clarification from JH - 07/04/2022"
|-
|-
|Myeloid proliferations associated with Down syndrome
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]]
|Disease
|Disease
|
|
Line 615: Line 755:
|JH_MS
|JH_MS
|
|
|
|Prior author:
Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome  +  Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome  +  Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
Line 622: Line 763:
|
|
|-
|-
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 638: Line 779:
|
|
|-
|-
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 654: Line 795:
|
|
|-
|-
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 670: Line 811:
|
|
|-
|-
|Myeloid/lymphoid neoplasm with JAK2 rearrangement
|[[HAEM5:Myeloid/lymphoid neoplasm with JAK2 rearrangement|Myeloid/lymphoid neoplasm with JAK2 rearrangement]]
|Disease
|Disease
|ISSUE- FOX
|ISSUE- FIX




Line 689: Line 830:
|
|
|-
|-
|Myeloid/lymphoid neoplasm with FLT3 rearrangement
|[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement|Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
|Disease
|Disease
|
|
Line 699: Line 840:
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
|Disease
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|9/22/24
|
|
|Pending
|
|
|FQR
|
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]]
|Disease
|Disease
|Rolando Garcia
|2/7/2025
|
|
|Pending
|
|
|FQR
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
|Disease
|Tracy Tucker, PhD, FCCMG
|4/6/24
|
|
|FQR
|Pending
|
|
|
|
|JH_MS
|
|
|
|
|Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1
|Tracy Tucker, PhD, FCCMG
|Complete
|
|
|
|
|-
|-
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
|Disease
|Disease
|Tracy Tucker, PhD, FCCMG
|4/6/24
|
|
|Pending
|
|
|JH_MS
|
|
|
|
|Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged
|Tracy Tucker, PhD, FCCMG
|Complete
|
|
|FQR
|
|
|-
|[[HAEM5:Acute leukaemia of ambiguous lineage with other defined genetic alterations|Acute leukaemia of ambiguous lineage with other defined genetic alterations]]
|Disease
|
|
|
|
Line 735: Line 933:
|
|
|
|
|JH_MS
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
|Disease
|Disease
|Tracy Tucker, PhD, FCCMG
|(Rabail Aslam, MD)
|
Shashi Shetty, Ph.D.
|
|7/1/24
|
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|
|
|Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified
|
|Priyatharsini Nirmalanantham, MD and  Shashi Shetty, PhD
|
|Complete
|
|
|
|
|-
|-
|Mixed-phenotype acute leukaemia with KMT2A rearrangement
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
|Disease
|Disease
|Tracy Tucker, PhD, FCCMG
|PENDING
|
|
|
|
Line 762: Line 968:
|JH_MS
|JH_MS
|
|
|emailed 5/1/24
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
|Complete
|
|
|-
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
|Disease
|Daynna Wolff, PhD
|5/9/24
|
|
|Pending
|
|
|JH_MS
|
|
|
|
|Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types
|Elicia Goodale, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|PENDING
|
|
|
|
|-
|-
|Acute leukaemia of ambiguous lineage with other defined genetic alterations
|[[HAEM5:Acute leukaemia of ambiguous lineage, NOS|Acute leukaemia of ambiguous lineage, NOS]]
|Disease
|Disease
|
|
Line 779: Line 1,001:
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
|Disease
|(Rabail Aslam, MD)
Shashi Shetty, Ph.D.
|7/1/24
|
|
|Pending
|
|
|JH_MS
|
|
|
|
|Acute Undifferentiated Leukemia
|Amelia Nakanishi, MD and Shashi Shetty, PhD
|Complete
|
|
|Check reference format
|-
|-
|Mixed-phenotype acute leukaemia, B/myeloid
|Disease
|Priyatharsini Nirmalanantham, MD and  Shashi Shetty, PhD
|
|
====CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)====
|
|
----<br />
|
|
----<br />
|
|
|JH_MS
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Mixed-phenotype acute leukaemia, T/myeloid
|Disease
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|JH_MS
----<br />
|-
|[[HAEM5:Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm]]
|Disease
|
|
|
|
Line 814: Line 1,062:
|
|
|
|
|Greg Corboy (GC)
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mixed-phenotype acute leukaemia, rare types
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]
|Disease
|Disease
|Elicia Goodale, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|Daynna Wolff
|5/3/2025
|8/3/2025
|Pending
|
|
|GC
|
|
|
|
|Blastic Plasmacytoid Dendritic Cell Neoplasm
|Hao Liu, MD and Daynna J. Wolff, PhD
|Complete
|
|
|JH_MS
|Previously within myeloid section under JH/MS editors
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
|Disease
|
|
|
|
Line 830: Line 1,110:
|
|
|
|
|GC
|
|
|
|
|Langerhans Cell Histiocytosis
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Complete
|5/19/2022 Emailed 5/6/2025, no reply<br />
|Date completed by author: 04/28/2022
|-
|-
|Acute leukaemia of ambiguous lineage, NOS
|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]]
|Disease
|Disease
|
|
Line 840: Line 1,126:
|
|
|
|
|JH_MS
|GC
|
|
|
|
|
|
|
|
|
|Langerhans Cell Sarcoma
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Complete
|5/19/2022 Emailed 5/6/2025, no reply<br />
|Date completed by author: 04/28/2022
|-
|-
|Acute undifferentiated leukaemia
|[[HAEM5:Indeterminate dendritic cell tumour|Indeterminate dendritic cell tumour]]
|Disease
|Disease
|Amelia Nakanishi, MD and Shashi Shetty, PhD
|
|
|
|
|
|
|
|
|JH_MS
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]]
|Disease
|Muhammad Zulfiqar, MD
|7/4/2025
|10/4/2025
|Pending
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]]
|Disease
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|9/22/24
|12/22/24 Emailed 9/4/2025 to remind
|Pending
|
|
|-
|GC
|CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)
|
----<br />
|
|
----<br />
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]]
|Disease
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|9/22/24
|12/22/24 Emailed 9/4/2025 to remind
|Pending
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]]
|Disease
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|9/22/24
|12/22/24 Emailed 9/4/2025 to remind
|Pending
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:ALK-positive histiocytosis|ALK-positive histiocytosis]]
|Disease
|
|
|
|
Line 882: Line 1,222:
|
|
|
|
|GC
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]]
|Disease
|Disease
|
|
Line 890: Line 1,238:
|
|
|
|
|Greg Corboy (GC)
|GC
|
|
|
|
|Histiocytic Sarcoma
|Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic
|Complete
|10/01/2021
|Date completed by author: 10/01/2021. Emailed both authors 5/1/2025, no reply.
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|
|
====CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Blastic plasmacytoid dendritic cell neoplasm
|Disease
|Hao Liu, MD and Daynna J. Wolff, PhD
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|GC
----<br />
|
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|Langerhans cell histiocytosis
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]]
|Disease
|Disease
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Muhammad Zulfiqar, MD
|7/4/2025
|10/4/2025 Emailed 9/4/2025 to remind
|Pending
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:IgG4-related disease|IgG4-related disease]]
|Disease
|Muhammad Zulfiqar, MD
|7/4/2025
|10/4/2025 Emailed 9/4/2025 to remind
|Pending
|
|
|GC
|GC
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Unicentric Castleman disease|Unicentric Castleman disease]]
|Disease
|
|
|
|
Line 928: Line 1,333:
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Langerhans cell sarcoma
|[[HAEM5:Idiopathic multicentric Castleman disease|Idiopathic multicentric Castleman disease]]
|Disease
|Disease
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|
|
|
|
|
Line 941: Line 1,352:
|
|
|
|
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|-
|-
|Indeterminate dendritic cell tumour
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]]
|Disease
|Disease
|
|
Line 957: Line 1,368:
|
|
|
|
|Multicentric Castleman Disease
|Sudha Arumugam, MD
|Complete
|01/24/2022. Emailed 5/1/2025, no response
|Date completed by author: 01/24/2022
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|Disease
|PENDING
|
|
|
|
|
|
|
|
|Holli Drendel (HD)
|
|
|-
|Interdigitating dendritic cell sarcoma
|Disease
|
|
|B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified
|Holli Drendel
|PENDING
|
|
|
|
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
|Disease
|PENDING
|
|
|
|GC
|
|
|
|
|
|
|HD
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|PENDING
|
|
|
|
|-
|-
|Juvenile xanthogranuloma
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
|Disease
|Disease
|PENDING
|
|
|
|
|
|
|
|
|
|HD
|GC
|
|
|
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy
|Ashwini Yenamandra PhD FACMG  Lisa Smith PhD FACMG  Yassmine Akkari PhD FACMG
|Complete
|
|
|
|
|-
|-
|Erdheim-Chester disease
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
|Disease
|Disease
|Holli Drendel
|
|
|
|
|?Complete? Looks like tables need more editing.
|
|
|HD
|
|
|
|
|GC
|B-Lymphoblastic Leukemia/Lymphoma with iAMP21 [but was completed as a 5th edition page by Holli]
|Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte
|?Complete
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
|Disease
|PENDING
|
|
|
|
|
|
|
|HD
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|PENDING
|
|
|
|
|-
|-
|Rosai-Dorfman Disease
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|Disease
|Disease
|PENDING
|
|
|
|
|
|
|
|
|HD
|
|
|GC
|
|
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
|Mark G. Evans, MD, University of California, Irvine  Fabiola Quintero-Rivera, MD, University of California, Irvine
|Complete
|
|
|
|
|-
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
|Disease
|PENDING
|
|
|
|
|
|
|
|
|-
|HD
|ALK-positive histiocytosis
|Disease
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged
|Yassmine Akkari  Nicolas Millan
|PENDING
|
|
|
|
|-
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
|Disease
|PENDING
|
|
|GC
|
|
|
|
|
|
|HD
|
|
|
|
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion
|Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG  Cancer Category/Type    B-Lymphoblastic Leukemia/Lymphoma
|PENDING
|
|
|
|
|-
|-
|Histiocytic sarcoma
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
|Disease
|Disease
|Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic
|Lei Zhang and Michelle Fan (trainee)
|8/8/2024
|
|
|Pending
|
|
|HD
|
|
|
|
|GC
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
|Disease
|PENDING
|
|
|
|
|
|
|
|HD
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|PENDING
|
|
|
|
|-
|-
|CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
|
|Disease
----<br />
|PENDING
|
----<br />
|
|
|
|
|
|
|
|
|HD
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|PENDING
|
|
|
|
|-
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]]
|Disease
|Aiko Otsubo
|6/25/2024
|
|
|Pending
|
|
|HD
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
|Disease
|Disease
|Lei Zhang and Michelle Fan (trainee)
|8/8/2024
|
|
|Pending
|
|
|HD
|
|
|
|
|
|NEW (No Prior)
|GC
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
|Disease
|
|
|
|
Line 1,090: Line 1,605:
|
|
|
|
|HD
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|IgG4-related disease
|RESOLVE 4th edition ALL-Related NON-WHO entities content
|Disease
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|ISSUE- FIX
 
 
Resolve Non-WHO entities
|
|
|
|
Line 1,100: Line 1,641:
|
|
|
|
|GC
|
|
|
|
|
|
|ISSUE - FIX
|
|
|
|
|
|
|-
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
| ||9/4/2025 sent E-mail reminder|| || ||Shivani Golem (SG)
| ||
|Monoclonal B-cell Lymphocytosis
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
|PENDING, 4/30/2024
|
|
|Assigned 12/19/2022 with completion date of 1/19/2023
|-
|-
|Unicentric Castleman disease
|[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa
|Disease
 
Renee Eigsti, MD, Pathology Services of Kalamazoo
 
Honey Reddi, PhD, Belay Diagnostics
| || ||Complete|| ||SG|| ||
|Already converted to 5th edition
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
|
|
|
|
|
|
|-
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||Michael Lack, MD, KUMC (trainee)/Shivani Golem
|7/16/24||9/4/2025 sent E-mail reminder||PENDING|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Hairy Cell Leukemia
|Snehal Patel, MD, PhD
|Pending WHO 5th e. July 2024
|
|
|
|
|GC
|-
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||Madhu Pantrangi
|4/15/25|| ||9/4/2025 sent E-mail reminder|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Splenic Marginal Zone Lymphoma
|Snehal Patel, MD, PhD
|Complete
|
|
|
|
|-
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||
| || || || ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
|Snehal Patel, MD, PhD
|Complete
|
|
|
|
|-
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
|Disease
|
|
|
|
|
|
|-
|Idiopathic multicentric Castleman disease
|Disease
|
|
|
|
|SG
|
|
|Need new author to update latest content. Prior author cannot update the page.
|Hairy Cell Leukemia Variant
|Snehal Patel, MD, PhD
|Complete
|
|
|
|
|GC
|-
|
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]
|Disease
|
|
|
|
|Sent e-mail to prev authors no reply
|
|
|
|
|SG
|
|
|Email sent to request to update 2024
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
|Complete
|4/12/2023 by FQR
|
|
|-
|-
|KSHV/HHV8-associated multicentric Castleman disease
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]
|Disease
|Disease
|Sudha Arumugam, MD
|
|
|
|
|Sent e-mail to prev authors no reply
|
|
|
|
|GC
|SG
|
|
|Email sent to request to update 2024
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
Department of Pathology and Laboratory Medicine and *Pediatrics, School of Medicine, University of California Irvine (UCI)
|Complete
|4/12/23 by FQR
|
|
|-
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]]
|Disease
|Molly Walkenhorst
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|SG
|
|
|
|
|NEW (No Prior)
|Molly Walkenhorst, DO and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|B-lymphoblastic leukaemia/lymphoma
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]
|Disease
|Disease
|Andrew Ly
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|SG
|
|
|
|
|Holli Drendel (HD)
|Nodal Marginal Zone Lymphoma
|Andrew Ly, DO and Shivani Golem, PhD, FACMG
|Complete
|5/28/2021
|
|-
|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]]
|Disease
|
|
|
|
Line 1,170: Line 1,799:
|
|
|
|
|SG
|
|
|Need new author to update latest content. Prior authors cannot update the page.
|Paediatric Nodal Marginal Zone Lymphoma
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
|Complete; Need new author to update latest content. Primary author cannot update the page.
|11/11/2020
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy
|[[HAEM5:In situ follicular B-cell neoplasm|In situ follicular B-cell neoplasm]]
|Disease
|Disease
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|Pending
|
|
|SG
|
|
|
|
|
|In Situ Follicular Neoplasia
|HD
|Rachel D. Burnside, PhD, MBA, FACMGG
|
|Pending
|
|
|
|
|-
|[[HAEM5:Follicular lymphoma|Follicular lymphoma]]
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|Pending
|
|
|SG
|
|
|Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity
|(1) Follicular Lymphoma + (2) Testicular Follicular Lymphoma
|(1 and 2) Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
|Pending
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with hypodiploidy
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]
|Disease
|Disease
|Ashwini Yenamandra PhD FACMG  Lisa Smith PhD FACMG  Yassmine Akkari PhD FACMG
|Rachel D. Burnside, PhD, MBA, FACMGG
|
|
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|
|
|
|
|SG
|
|
|HD
|Need new author to update latest content. Prior authors cannot update the page.
|Paediatric-Type Follicular Lymphoma
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
|Complete; Need new author to update latest content. Primary author  cannot update the page.
|8/16/2020
|
|
|-
|[[HAEM5:Duodenal-type follicular lymphoma|Duodenal-type follicular lymphoma]]
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside no reply 7/17/
|Pending
|
|
|SG
|
|
|
|
|Duodenal-Type Follicular Lymphoma
|No prior content
|
|
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with iAMP21
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]
|Disease
|Disease
|Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte
|Linlin Gao
|
|
|
|
|HD
|
|
|
|9/4/2025 Sent E-mail to remind
|
|
|
|
|SG
|
|
|
|
|Primary Cutaneous Follicle Centre Lymphoma
|Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG
|Complete
|09/10/2022
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]
|Disease
|Disease
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|
|
|
|
|
|HD
|
|
|
|
|
|
|
|
|SG
|
|
|
|
|In Situ Mantle Cell Neoplasia
|Rina Kansal, MD; Versiti Blood Center of Wisconsin
|Complete
|7/26/2022
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]]
|Disease
|Disease
|Mark G. Evans, MD, University of California, Irvine  Fabiola Quintero-Rivera, MD, University of California, Irvine
|PENDING
|
|
|9/4/2025 set E-mail reminder
|
|
|
|
|SG
|
|
|HD
|
|
|Mantle Cell Lymphoma
|Mahsa Khanlari, MD and  Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
|Pending
|
|
|Target completion date 8/15/20
|-
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]]
|Disease
|Farhan Sami
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|SG
|
|
|
|
|NEW (No Prior)
|Farhan Sami, MD and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]]
|Disease
|Disease
|Yassmine Akkari  Nicolas Millan
|Farhan Sami
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|SG
|
|
|HD
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation
|
|NEW (No Prior)
|
|Farhan Sami, MD and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||
| || || || ||GC|| ||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
|Pending
|
|
|Requested to update 14022022
|-
|[[HAEM5:T-cell/histiocyte-rich large B-cell lymphoma|T-cell/histiocyte-rich large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|5/6/2025||8/6/2025 Emailed 9/4/2025 to remind|| || ||GC|| ||
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|Complete
|24/02/2022
|
|
|-
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||
| || || || ||GC|| ||
|ALK-Positive Large B-cell Lymphoma
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
|
|
|
|
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
|-
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||
| || || || ||GC|| ||
|Large B-cell Lymphoma with IRF4 Rearrangement
|Afia Hasnain, MBBS, PhD
|Complete
|5/26/2021. Emailed 5/7//2025, no reply
|
|
|-
|-
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||
|Disease
| || || || ||GC|| ||
|Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG  Cancer Category/Type    B-Lymphoblastic Leukemia/Lymphoma
|Burkitt-Like Lymphoma with 11q Aberration
|
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|
|Complete
|
|27/01/2022  Emailed 5/7//2025, no reply
|
|HD
|
|
|
|
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features
|[[HAEM5:Lymphomatoid granulomatosis|Lymphomatoid granulomatosis]]||Disease|| || || || || ||GC|| ||
|Disease
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|-
|HD
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee) + Andrew Siref as mentor
|
|3/22/24|| ||Pending|| ||GC|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|-
|-
|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion
|[[HAEM5:Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma associated with chronic inflammation]]||Disease|| || || || || ||GC|| ||
|Disease
|NEW (No Prior)
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|-
|HD
!Disease (5th Edition)
|
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|
!Date Assigned to Author (5th Edition)
|
!Target Completion Date (5th Edition)
|
!Content Status (5th Edition)(Pending or Complete)
|
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Fluid overload-associated large B-cell lymphoma|Fluid overload-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||
| || || || ||GC|| ||
|Plasmablastic Lymphoma
|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
|Complete
|28/03/2022
|
|
|-
|-
|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
|Disease
|6/28/2025
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|9/28/2025 Emailed 9/4/2025 to remind.|| || ||GC|| ||
|
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS
|
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
|
|(1) Pending + (2) Complete
|
|(1) Not ready + (2) 03/28/22
|HD
|For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022
|-
|[[HAEM5:Primary cutaneous diffuse large B-cell lymphoma, leg type|Primary cutaneous diffuse large B-cell lymphoma, leg type]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|5/6/2025
|8/6/2025 Emailed 9/4/2025 to remind
| || ||GC|| ||
|Intravascular Large B-cell Lymphoma
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy
|Complete
|9/1/22
|Emailed 28/3/2022 for progress update
|-
|[[HAEM5:Primary mediastinal large B-cell lymphoma|Primary mediastinal large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Mediastinal grey zone lymphoma|Mediastinal grey zone lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||
| || || || ||GC|| ||
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)
|Aiko Otsubo, PhD, Indiana University, Holli Drendel
|Complete
|16/11/2021 Emailed 5/6/2025, no reply
|
|
|-
|[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||
| || || || ||GC|| ||
|Burkitt Lymphoma
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
|Complete
|28/06/2021 Emailed 5/6/2025, no reply
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:KSHV/HHV8-positive diffuse large B-cell lymphoma|KSHV/HHV8-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:KSHV/HHV8-positive germinotropic lymphoproliferative disorder|KSHV/HHV8-positive germinotropic lymphoproliferative disorder]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content.  What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.|| || || || ||GC|| ||
|
|
|
|
Line 1,333: Line 2,176:
|
|
|-
|-
|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion
|[[HAEM5:Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]].
|Disease
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"
| || || || ||GC|| ||
|Polymorphic Post-Transplant Lymphoproliferative Disorders
|Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)
|Completed
|26/4/2022
|
|
|-
|[[HAEM5:EBV-positive mucocutaneous ulcer|EBV-positive mucocutaneous ulcer]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Lymphomas arising in immune deficiency / dysregulation|Lymphomas arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| ||
|
|
|
|
|
|
|
|
|HD
|
|
|-
|[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.|| || || || ||GC|| ||
|
|
|
|
Line 1,347: Line 2,205:
|
|
|
|
|-
|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||Xiaolin Hu
|5/7/2025
|8/7/2025 Reminder email sent 9/4/2025|| ||
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez
|Pending + Completed (03/21/22)
|Not completed for checking (1, 3 and 4) + 03/21/22 (2)
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations
|[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease||Muhammad Zulfiqar, MD
|Disease
|7/4/2025
|
|10/4/2025 Reminder email sent 9/4/2025||Pending|| ||GC|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|HD
|NEW (No Prior)
|
|-
|
!Disease (5th Edition)
|
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|
!Date Assigned to Author (5th Edition)
|
!Target Completion Date (5th Edition)
|
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|B-lymphoblastic leukaemia/lymphoma, NOS
|[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]]
|Disease
|Disease
|
|
Line 1,372: Line 2,248:
|
|
|
|
|HD
|SG
|
|
|
|
|
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:IgM monoclonal gammopathy of undetermined significance|IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Non-IgM monoclonal gammopathy of undetermined significance|Non-IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Monoclonal gammopathy of renal significance|Monoclonal gammopathy of renal significance]]||Disease|| || || || || ||SG
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|RESOLVE 4th edition ALL-Related NON-WHO entities content
|[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease||
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
| || || || ||SG
|ISSUE - FIX
| ||
|
|Primary Amyloidosis
|Heather E. Williams, PhD, MS, PgD, ErCLG
|?PENDING<br />
|
|
|
|
|-
|[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease||
| || || || ||SG
| ||
|Light Chain and Heavy Chain Deposition Disease
|Chen Yang, MD, PhD, University of Michigan
|Complete
|10/15/2022
|
|
|-
|[[HAEM5:Mu heavy chain disease|Mu heavy chain disease]]||Disease|| || || || || ||SG
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease||
| || || || ||SG
| ||
|Gamma Heavy Chain Disease
|Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA
|Complete
|5/26/2021
|
|
|-
|[[HAEM5:Alpha heavy chain disease|Alpha heavy chain disease]]||Disease|| || || || || ||SG
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||
| || || ||
|SG
| ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo and Zhenya Tang
|4/14/25||7/14/25
9/4/2025 Sent E-mail reminder to Dr. Tang
|Pending|| ||SG
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG
|Pending
|
|
|
|
|-
|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING
| ||9/4/2025 E-mail sent to Dr. Senaratne
| ||
|SG
| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
|(1) POEMS Syndrome + (2) TEMPI Syndrome
|(1 and 2) Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD
|?PENDING
|
|
|
|
|-
|Disease (5th Edition)
|Page Type
|Author (5th Edition) (Note: please indicate trainees in parenthesis)
|Date Assigned to Author (5th Edition)
|Target Completion Date (5th Edition)
|Content Status (5th Edition) (Pending or Complete)
|Date Completed by Author (5th Edition)
|Associate Editor
|Date of Last Editor Review (5th Edition)
|Notes (5th Edition)
|Correlated Prior Disease Name (4th Edition)
|Correlated Prior Author (4th Edition)
|Prior Content Status (4th Edition) (Pending or Complete)
|Prior Date of Last Editor Review (4th Edition)
|Prior Notes (4th Edition)
|-
|
|
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
|
|
----<br />
|
|
|-
----<br />
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
| ||
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|
|
|
|
|
----<br />
|
|
----<br />
|-
|-
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK)
|
| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee), Karin Miller, MD
|
|3/25/2024
|
| || || ||SK|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Indolent T-lymphoblastic proliferation|Indolent T-lymphoblastic proliferation]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli
|[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]]
|Disease
|Disease
|*Snehal Patel, MD, PhD
|Fei Yang, MD
|
|
|
|
|SG
|
|
|
|
|Pending
|
|
|SK
|
|
|
|
|Early T-Cell Precursor Lymphoblastic Leukemia
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
|Pending
|
|
|
|
|-
|-
|Lymphoplasmacytic lymphoma
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
|Disease
|Disease
|Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
|Parastou Tizro, MD (trainee); Celeste Eno, PhD
|3/17/2024
|
|
|Complete
|6/24/2024
|SK
|7/1/2024
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee); Michelle Don, MD, MS
|3/17/2024 (trainee name added on 9/9/24 by JH)
|6/30/24
|Pending
| ||SK|| ||
|T-cell Large Granular Lymphocytic Leukemia
|Michelle Don, MD, MS
|Pending
|
|
|
|
|SG
|-
|
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);
Michelle Don, MD, MS
|3/17/2024
|6/30/24
|Pending
| ||SK|| ||
|Chronic Lymphoproliferative Disorder of NK Cells
|Michelle Don, MD
|Pending
|
|
|
|
|-
|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||
| || || || ||SK|| ||
|Adult T-cell Leukemia/Lymphoma
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center
|?Pending
|
|
|
|
|-
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
| || || ||SK|| ||
|Sézary Syndrome
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
|Pending
|
|
|
|
|-
|-
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD
|Disease
|7/1/2024||8/31/2024
|
|Pending
|
| ||SK|| ||
|
|Aggressive NK-cell Leukemia
|
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD
|
|?Pending
|SG
|
|
|
|
|
|-
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc, Teodora Popa (resident)
|3/19/2024
| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee),
Andrew Siref, MD
|4/12/2024
| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
| || || ||SK|| ||
|Mycosis Fungoides
|Jane Scribner, MD and Daynna J. Wolff, PhD
|Pending
|
|
|
|
|-
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD
|7/1/2024
|8/31/224
|Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD
|7/1/2024||8/31/2024
|Pending
| ||SK|| ||
|Primary Cutaneous Anaplastic Large Cell Lymphoma
|Theresa Spivey, MD, Shashirekha Shetty, PhD
|Pending
|
|
|
|
|-
|-
|Primary cutaneous marginal zone lymphoma
!Disease (5th Edition)
|Disease
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|
!Date Assigned to Author (5th Edition)
|
!Target Completion Date (5th Edition)
|
!Content Status (5th Edition)(Pending or Complete)
|
!Date Completed by Author (5th Edition)
|SG
!Associate Editor
|
!Date of Last Editor Review (5th Edition)
|
!Notes (5th Edition)
|
!Correlated Prior Disease Name (4th Edition)
|
!Correlated Prior Author (4th Edition)
|
!Prior Content Status (4th Edition)(Pending or Complete)
|
!Prior Date of Last Editor Review (4th Edition)
|
!Prior Notes (4th Edition)
|-
|-
|Nodal marginal zone lymphoma
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
|Disease
|3/19/2024
|Andrew Ly, DO and Shivani Golem, PhD, FACMG
| ||Pending
|
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD
|6/30/2024
| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee),
 
Andrew Siref, MD
|4/12/2024|| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous peripheral T-cell lymphoma, NOS|Primary cutaneous peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
| || || || ||SK|| ||
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|Pending
|
|
|
|
|-
|[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
Andrew Siref, MD
|3/20/2024
| ||Pending|| ||SK|| ||
|Enteropathy-Associated T-cell Lymphoma
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
|Complete
|1/21/2021
|
|
|SG
|-
|
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
|
Andrew Siref, MD
|3/20/2024
| ||Pending|| ||SK|| ||
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|Pending
|
|
|
|
|-
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||
| || || || ||SK|| ||
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
|Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)
|Complete
|9/26/2022
|
|
|-
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);
Michelle Don, MD, MS
|3/19/2024
|6/30/24
|Complete
|5/13/24||SK||10/18/24||
|Hepatosplenic T-cell Lymphoma
|Michelle Don, MD, MS
|Complete
|1/21/2021
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
Sumire Kitahara, MD
|6/6/24|| ||Pending
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Positive
|Miguel Gonzalez Mancera, MD
Sumire Kitahara, MD
Cedars-Sinai, Los Angeles, CA
|Complete
|09/23/2022
|
|
|-
|-
|Paediatric nodal marginal zone lymphoma
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
|Disease
Sumire Kitahara, MD
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
|6/6/24|| ||Pending
|
| ||SK|| ||
|
|Anaplastic Large Cell Lymphoma, ALK-Negative
|
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
|
|Complete
|SG
|09/23/2022
|
|
|
|
|-
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
|4/1/2024
| ||Pending|| ||SK|| ||
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
|Pending
|
|
|
|
|-
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
| ||Pending|| ||SK|| ||prior authors not available
|Angioimmunoblastic T-cell Lymphoma
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
|Pending
|
|
|
|
|-
|-
|In situ follicular B-cell neoplasm
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|Disease
| ||Pending|| ||SK|| ||
|Rachel D. Burnside, PhD, MBA, FACMGG
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|SG
|
|
|
|
|
|
|
|-
|-
|Follicular lymphoma
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||
|Disease
| || || || ||SK|| ||
|Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
|
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
|
|Pending
|
|
|SG
|
|
|
|
|
|
|
|
|
|-
|-
|Paediatric-type follicular lymphoma
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|Disease
|6/25/2023
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
| || || ||SK|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|SG
|NEW (No Prior)
|
|-
|
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), Andrew Siref, MD||3/22/2024|| ||Pending|| ||SK|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|-
|-
|Duodenal-type follicular lymphoma
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc, Teodora Popa (resident)
|Disease
|3/19/2024
|
| ||Pending
|
| ||SK|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|SG
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Severe mosquito bite allergy|Severe mosquito bite allergy]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
|3/25/2024
| || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
|3/25/2024
| || || ||SK|| ||prior authors not available
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
|Complete
|11/21/2021
|
|
|-
|
|
====CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)====
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Primary cutaneous follicle centre lymphoma
|Disease
|Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|SG
----<br />
|
|
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|In situ mantle cell neoplasm
|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]]
|Disease
|Disease
|Rina Kansal, MD; Versiti Blood Center of Wisconsin
|
|
|
|
|
|
|SG
|
|
|
|
|
|
|GC
|
|
|
|
|Follicular Dendritic Cell Sarcoma
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
|?Pending
|
|
|
|
|-
|-
|Mantle cell lymphoma
|[[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma|EBV-positive inflammatory follicular dendritic cell sarcoma]]
|Disease
|Disease
|* Mahsa Khanlari, MD * Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
|
|
|
|
|SG
|
|
|
|
Line 1,638: Line 2,909:
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Leukaemic non-nodal mantle cell lymphoma
|[[HAEM5:Fibroblastic reticular cell tumour|Fibroblastic reticular cell tumour]]
|Disease
|Disease
|<br />
|
|
|
|
|SG
|
|
|
|
Line 1,654: Line 2,925:
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Transformations of indolent B-cell lymphomas
|[[HAEM5:Intranodal palisaded myofibroblastoma|Intranodal palisaded myofibroblastoma]]
|Disease
|Disease
|
|
Line 1,664: Line 2,941:
|
|
|
|
|SG
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Littoral cell angioma|Littoral cell angioma]]
|Disease
|
|
|
|
Line 1,672: Line 2,973:
|
|
|
|
|-
|GC
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
|
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Splenic hamartoma|Splenic hamartoma]]
|Disease
|
|
|
|
|-
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
|[[HAEM5:Sclerosing angiomatoid nodular transformation (SANT) of spleen|Sclerosing angiomatoid nodular transformation (SANT) of spleen]]
|Disease
|
|
|
|
Line 1,693: Line 3,005:
|
|
|
|
|-
|GC
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|
|
====CHAPTER 7 (GENETIC TUMOUR SYNDROMES)====
|
|
----<br />
|
|
|-
----<br />
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
|
|
|
|
|
----<br />
|
|
----<br />
|-
|-
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
|
|N/A||N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|N/A
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
|[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|N/A
|N/A
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]||N/A||N/A||N/A||N/A||N/A||N/A||N/A
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|-
|-
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:RASopathies|RASopathies]]||Disease|| || || || || ||NA|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|-
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
|
|
|
|
|
|-
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
|
|
|
|
|
|-
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
|
|
|
|
|
|-
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
|
|
|
|
|
|-
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
|
|
|
|
|
|-
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
|
|
|
|
|
|-
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
|
|
|
|
|
|-
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Cold agglutinin disease
|Disease
|
|
|
|
|
|SG
|
|
|
|
|
|
|
|-
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
|
|
|
|
|
|-
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
|
|
|
|
|
|-
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
| ||
|
|
|
|
|
|-
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
| ||
|
|
|
|
|
|-
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
| ||
|
|
|
|
|
|-
|Mu heavy chain disease||Disease|| || || || || ||SG
| ||
|
|
|
|
|
|-
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
| ||
|
|
|
|
|
|-
|Alpha heavy chain disease||Disease|| || || || || ||SG
| ||
|
|
|
|
|
|-
|Plasmacytoma||Disease|| || || || || ||SG
| ||
|
|
|
|
|
|-
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
| ||
|
|
|
|
|
|-
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
| ||
|
|
|
|
|
|-
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
|
----<br />
|
----<br />
|
|
|
|
|
|
|
|
|
|
|
|
|-
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
| ||
|
|
|
|
|
|-
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
|
|
|
|
|
|-
|Early T-precursor lymphoblastic leukaemia / lymphoma
|Disease
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
|
|
|
|
|HD
|
|
|
|
|
|
|
|-
|T-prolymphocytic leukaemia
|Disease
|
|
|
|
|
|SK
|
|
|
|
|
|
|
|-
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
|
|
|
|
|
|-
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
|
|
|
|
|
|-
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
|
|
|
|
|
|-
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)   Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
|
|
|
|
|
|-
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
|
|
|
|
|
|-
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
|
|
|
|
|
|-
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
|
|
|
|
|
|-
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
|
|
|
|
|
|-
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
|
|
|
|
|
|-
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
|
----<br />
|
----<br />
|
|
|
|
|
|
|
|
|
|
|
|
|-
|Follicular dendritic cell sarcoma
|Disease
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|EBV-positive inflammatory follicular dendritic cell sarcoma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|Fibroblastic reticular cell tumour
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|Intranodal palisaded myofibroblastoma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|Littoral cell angioma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|Splenic hamartoma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|Sclerosing angiomatoid nodular transformation (SANT) of spleen
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|CHAPTER 7 (GENETIC TUMOUR SYNDROMES)
|
----<br />
|
----<br />
|
|
|
|
|
|
|
|
|
|
|
|
|-
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|-
|Bloom syndrome||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|-
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|-
|RASopathies||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|}
|}
Retrieved from "https://test.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"